Navigation Links
Lyme disease bacteria take cover in lymph nodes
Date:6/16/2011

The bacteria that cause Lyme disease, one of the most important emerging diseases in the United States, appear to hide out in the lymph nodes, triggering a significant immune response, but one that is not strong enough to rout the infection, report researchers at the University of California, Davis.

Results from this groundbreaking study involving mice may explain why some people experience repeated infections of Lyme disease. The study appears online in the journal Public Library of Science Biology at: http://tinyurl.com/3vs8pm9.

"Our findings suggest for the first time that Borrelia burgdorferi, the bacteria that cause Lyme disease in people, dogs and wildlife, have developed a novel strategy for subverting the immune response of the animals they infect," said Professor Nicole Baumgarth, an authority on immune responses at the UC Davis Center for Comparative Medicine.

"At first it seems counter intuitive that an infectious organism would choose to migrate to the lymph nodes where it would automatically trigger an immune response in the host animal," Baumgarth said. "But B. burgdorferi have apparently struck an intricate balance that allows the bacteria to both provoke and elude the animal's immune response."

About Lyme disease

Lyme disease, the most important tick-borne disease in the United States is caused by Borrelia burgdorferi, corkscrew-shaped bacteria also known as spirochetes. The disease is transmitted to humans and animals through bites from infected deer ticks.

The disease occurs mainly in the Northeastern and Great Lakes states, and is present to a lesser extent in Northern California. However, the western black-legged tick, the main carrier of Lyme disease in the western United States, has been found in 56 of California's 58 counties, according to the California Department of Public Health.

Symptoms of Lyme disease are quite variable and may include fever, headache, fatigue and a skin rash. If the infection is not treated, it can spread to the joints, heart and nervous system.

Usually, Lyme disease can be successfully treated with about four weeks of antibiotics; treatment is most successful during the early stages of infection.

The UC Davis study

Swollen lymph nodes, or lymphadenopathy, is one of the hallmarks of Lyme disease, although it has been unclear why this occurs or how it affects the course of the disease. The UC Davis research team set out to explore in mice the mechanisms that cause the enlarged lymph nodes and to determine the nature of the resulting immune response.

They found that when mice were infected with B. burgdorferi, these live spirochetes accumulated in the animals' lymph nodes. The lymph nodes responded with a strong, rapid accumulation of B cells, white blood cells that produce antibodies to fight infections. Also, the presence of B. burgdorferi caused the destruction of the distinct architecture of the lymph node that usually helps it to function normally.

While B cells accumulated in large numbers and made some specific antibodies against B. burgdorferi, they did not form "germinal centers," structures that are needed for the generation of highly functional and long-lived antibody responses.

"Overall, these findings suggest that B. burgdorferi hinder the immune system from generating a response that is fully functional and that can persist and protect after repeat infections," Baumgarth said. "Thus, the study might explain why people living in endemic areas can be repeatedly infected with these disease-causing spirochetes."


'/>"/>

Contact: Patricia Bailey
pjbailey@ucdavis.edu
530-752-9843
University of California - Davis
Source:Eurekalert

Related biology news :

1. GW researchers receive award from NCI to study cancer from a neglected tropical disease
2. First diagnostic test for hereditary childrens disease
3. Scientists find deadly amphibian disease in the last disease-free region of central America
4. Genome sequence could reveal Achilles heels of important wheat disease
5. Potential treatment for deadly E. coli disease
6. Developmental disease is recreated in an adult model
7. A promising new approach to autoimmune diseases
8. Patients with bowel disease eager to test fecal therapy
9. Harvard scientists see the early cellular cause of dry eye disease for the first time
10. Origins of XMRV deciphered, undermining claims for a role in human disease
11. Good guy or bad guy? Diagnosing stomach disease in pet reptiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... Research and Markets has announced the addition of the "Biometric ... to their offering. ... The biometric vehicle access system market, in terms of value, ... to 2021. The market is estimated to be USD 442.7 Million ... The growth of the biometric vehicle access system market is fueled ...
(Date:12/15/2016)... ... Research and Markets has announced the addition of the "Global ... The report forecasts the global military biometrics market to grow at a ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners has ... pioneering medical device for the treatment of Age-Related Macular Degeneration. , The company’s ... global regulatory consultancy that helps companies like ours secure government approvals for their ...
(Date:1/21/2017)... Colo. , Jan. 20, 2017 ... or the "Company"), announced that on January 14, 2017 ... plan under which the Company will terminate certain employees ... Bioptix Diagnostics, Inc.  The Company commenced terminations on January ... within 30 days.  The Company may pay severance benefits ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
Breaking Biology Technology: